FDA Approves Gene Therapy for Rare Deafness Form: NPR

Bassyonni

Published: April 23, 2026 8:14 PM ET

The recent approval of a groundbreaking gene therapy by the Food and Drug Administration (FDA) marks a significant advancement in treating a rare form of genetic deafness. This therapy is designed to restore hearing in individuals born with a specific defect affecting the OTOF gene, crucial for sound transmission from the ears to the brain.

FDA Approves Gene Therapy for Rare Deafness

On Thursday, the FDA greenlit the first-ever gene therapy aimed at addressing congenital deafness. This decision is considered a historic milestone, as it signifies the first approved treatment specifically for hearing loss. The development has been met with enthusiasm within the medical community, heralded as a transformative step forward.

Case Study: Travis Smith

Sierra Smith, a resident of East Greenbush, New York, shared her personal experience with her son, Travis. After failing his newborn hearing test, it was determined that Travis was born profoundly deaf due to a genetic defect. Smith recounted how, initially, doctors believed his hearing issues were temporary.

Upon discovering a potential treatment involving gene therapy at Columbia University, she eagerly sought the experimental option. This therapy introduces a harmless virus into the ear, delivering the missing otoferlin protein that enables sound perception.

Remarkable Outcomes from Treatment

The therapy has shown positive results in clinical trials involving 20 patients, all born with the OTOF gene defect.
Approximately 80% of patients experienced significant hearing restoration.
42% achieved normal hearing, with some able to hear whispers.
The effects have persisted for over two years, demonstrating sustained outcomes.

After undergoing the treatment, Smith noticed a dramatic change when Travis responded to sound for the first time while in the car. The moment of recognition was especially poignant for her, illustrating the profound impact of the therapy.

Future of Gene Therapy in Hearing Restoration

Jonathon Whitton, Vice President for Genetic Medicines at Regeneron Pharmaceuticals, expressed his excitement about the approval. He remarked on the significance of being able to offer families a solution that was previously unimaginable. The therapy is expected to be available for free in the United States within weeks.

While the therapy currently targets a rare genetic condition affecting about 50 children annually in the U.S., researchers are optimistic about the future application of gene therapies for more common forms of hearing loss caused by aging or environmental factors.

Ethical Considerations

Despite the positive aspects of the gene therapy, some experts raise concerns regarding the implications for the deaf community. Critics argue that focusing on medical interventions may perpetuate the stigma surrounding deafness, suggesting that it needs to be “fixed” for individuals to integrate into society.

Regardless of differing viewpoints, families like the Smiths are grateful for the options available. Sierra Smith expressed her joy at her son’s newfound ability to hear, emphasizing the transformative power of this innovative treatment.

In conclusion, the FDA’s approval of gene therapy for a rare form of deafness not only represents a groundbreaking achievement but also opens the door to future possibilities in hearing restoration. With continued advancements in genetic medicine, hope grows for those affected by hearing loss.